tradingkey.logo
搜尋

Biofrontera Inc

BFRI
添加自選
1.010USD
0.0000.00%
收盤 07/02, 13:00美東報價延遲15分鐘
11.76M總市值
虧損本益比TTM

Biofrontera Inc

1.010
0.0000.00%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

+6.70%

1月

-1.94%

6月

+39.31%

今年開始到現在

+77.19%

1年

+46.36%

關鍵數據
1.020今開
1.065最高
394.50K成交量
虧損本益比TTM
2.12本益比動
--股利TTM
3.39%換手率
1.010昨收
1.000最低
296.17K成交額
虧損本益比靜
-4.56市淨率
0.00%股息率 TTM
-53.58%ROA
1.19052週最高
2.25量比
-17.76M淨利潤
11.65M總股本
-0.9689每股盈餘TTM
0.85Beta
-339.04%ROE
0.53652週最低
6.44%振幅
79.02%毛利率
11.76M總市值
0.49回報/風險
5.04%風險率

TradingKey Biofrontera Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Biofrontera Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名99/157位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為6.00。中期看,股價處於平穩狀態。近一個月,市場表現一般,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Biofrontera Inc評分

相關信息

行業排名
99 / 157
全市場排名
274 / 4565
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Biofrontera Inc亮點

亮點風險
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
業績高增長
公司營業收入穩步增長,連續3年增長22.41%
業績增長期
公司處於發展階段,最新年度總收入41.70M美元
估值低估
公司最新PE估值-1.04,處於3年歷史低位
機構減倉
最新機構持股2.75M股,環比減少9.14%

分析師目標

基於 2 分析師
買入
評級
6.000
目標均價
+488.24%
漲幅空間

Biofrontera Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Biofrontera Inc簡介

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
公司代碼BFRI
公司Biofrontera Inc
CEOLuebbert (Hermann)
網址https://www.biofrontera-us.com/

常見問題

Biofrontera Inc(BFRI)的當前股價是多少?

Biofrontera Inc(BFRI)的當前股價是 1.01。

Biofrontera Inc 的股票代碼是什麼?

Biofrontera Inc的股票代碼是BFRI。

Biofrontera Inc股票的52週最高點是多少?

Biofrontera Inc股票的52週最高點是1.19。

Biofrontera Inc股票的52週最低點是多少?

Biofrontera Inc股票的52週最低點是0.54。

Biofrontera Inc的市值是多少?

Biofrontera Inc的市值是12.93M。

現在Biofrontera Inc(BFRI)的股票是買入、持有還是賣出?

根據分析師評級,Biofrontera Inc(BFRI)的總體評級為買入,目標價格為6.00。

Biofrontera Inc(BFRI)股票的每股收益(EPS TTM)是多少

Biofrontera Inc(BFRI)股票的每股收益(EPS TTM)是-1.04。